{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T16:16:47Z","timestamp":1778170607433,"version":"3.51.4"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Austrian Science Funds","award":["P29343-B30"],"award-info":[{"award-number":["P29343-B30"]}]},{"name":"Austrian Science Funds","award":["I4754-B"],"award-info":[{"award-number":["I4754-B"]}]},{"DOI":"10.13039\/501100011852","name":"Paracelsus Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011960","name":"DEBRA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cutaneous squamous cell carcinoma (SCC) is the leading cause of death in patients with recessive dystrophic epidermolysis bullosa (RDEB). However, the survival time from first diagnosis differs between patients; some tumours spread particularly fast, while others may remain localized for years. As treatment options are limited, there is an urgent need for further insights into the pathomechanisms of RDEB tumours, to foster therapy development and support clinical decision-making.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate differences in RDEB tumours of diverging aggressiveness at the molecular and phenotypic level, with a particular focus on epithelial-to-mesenchymal (EMT) transition states and thus microRNA-200b (miR-200b) as a regulator.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Primary RDEB-SCC keratinocyte lines were characterized with respect to their EMT state. For this purpose, cell morphology was classified and the expression of EMT markers analysed using immunofluorescence, flow cytometry, semi-quantitative reverse transcriptase polymerase chain reaction and Western blotting. The motility of RDEB-SCC cells was determined and conditioned medium of RDEB-SCC cells was used to treat endothelial cells in an angiogenesis assay. In addition, we mined previously generated microRNA (miRNA) profiling data to identify a candidate with potential therapeutic relevance and performed transient miRNA transfection studies to investigate the candidate\u2019s ability to reverse EMT characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We observed high variability in EMT state in the RDEB-SCC cell lines, which correlated with in situ analysis of two available patient biopsies and respective clinical disease course. Furthermore, we identified miR-200b-3p to be downregulated in RDEB-SCCs, and the extent of deregulation significantly correlated with the EMT features of the various tumour lines. miR-200b-3p was reintroduced into RDEB-SCC cell lines with pronounced EMT features, which resulted in a significant increase in epithelial characteristics, including cell morphology, EMT marker expression, migration and angiogenic potential.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>RDEB-SCCs exist in different EMT states and the level of miR-200b is indicative of how far an RDEB-SCC has gone down the EMT path. Moreover, the reintroduction of miR-200b significantly reduced mesenchymal features.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad335","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T11:01:10Z","timestamp":1694170870000},"page":"80-93","source":"Crossref","is-referenced-by-count":7,"title":["MicroRNA-200b-mediated reversion of a spectrum of epithelial-to-mesenchymal transition states in recessive dystrophic epidermolysis bullosa squamous cell carcinomas"],"prefix":"10.1093","volume":"190","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8305-6135","authenticated-orcid":false,"given":"Julia","family":"Illmer","sequence":"first","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Zauner","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josefina","family":"Pi\u00f1\u00f3n Hofbauer","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Wimmer","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Gruner","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Ablinger","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Bischof","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Dorfer","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Hainzl","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Tober","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shir","family":"Bergson","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Tel-Aviv Sourasky Medical Center , Tel-Aviv , Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv , Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Sarig","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Tel-Aviv Sourasky Medical Center , Tel-Aviv , Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liat","family":"Samuelov","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Tel-Aviv Sourasky Medical Center , Tel-Aviv , Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv , Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Guttmann-Gruber","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruby","family":"Shalom-Feuerstein","sequence":"additional","affiliation":[{"name":"Department of Genetics and Developmental Biology, The Rappaport Faculty of Medicine and Research Institute, Technion Israel Institute of Technology , Haifa , Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli","family":"Sprecher","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Tel-Aviv Sourasky Medical Center , Tel-Aviv , Israel"},{"name":"Sackler Faculty of Medicine, Tel-Aviv University , Tel-Aviv , Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"Koller","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Laimer","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"},{"name":"Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6085-9170","authenticated-orcid":false,"given":"Johann W","family":"Bauer","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"},{"name":"Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Wally","sequence":"additional","affiliation":[{"name":"EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology and Allergology, University Hospital of the Paracelsus Medical University Salzburg , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"2023122107172263200_ljad335-B1","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225707","article-title":"Epidermolysis bullosa-associated squamous cell carcinoma: from pathogenesis to therapeutic perspectives","volume":"20","author":"Condorelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2023122107172263200_ljad335-B2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjd.19421","article-title":"Heterogeneous addiction to transforming growth factor-beta signalling in recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma","volume":"184","author":"Dayal","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023122107172263200_ljad335-B3","doi-asserted-by":"crossref","DOI":"10.3390\/cells11081365","article-title":"Squamous cell carcinoma in patients with inherited epidermolysis bullosa: review of current literature","volume":"11","author":"Bonamonte","year":"2022","journal-title":"Cells"},{"key":"2023122107172263200_ljad335-B4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986\u20132006","volume":"60","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"2023122107172263200_ljad335-B5","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3875","article-title":"Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study","volume":"101","author":"Robertson","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2023122107172263200_ljad335-B6","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.jaad.2014.01.903","article-title":"Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification","volume":"70","author":"Fine","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023122107172263200_ljad335-B7","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13023-016-0489-9","article-title":"Inherited epidermolysis bullosa and squamous cell carcinoma: a systematic review of 117 cases","volume":"11","author":"Montaudie","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"2023122107172263200_ljad335-B8","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.matbio.2018.01.016","article-title":"Injury- and inflammation-driven skin fibrosis: the paradigm of epidermolysis bullosa","volume":"68\u201369","author":"Nystrom","year":"2018","journal-title":"Matrix Biol"},{"key":"2023122107172263200_ljad335-B9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aas9668","article-title":"APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa","volume":"10","author":"Cho","year":"2018","journal-title":"Sci Transl Med"},{"key":"2023122107172263200_ljad335-B10","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"2023122107172263200_ljad335-B11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41586-018-0040-3","article-title":"Identification of the tumour transition states occurring during EMT","volume":"556","author":"Pastushenko","year":"2018","journal-title":"Nature"},{"key":"2023122107172263200_ljad335-B12","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","article-title":"The basics of epithelial-mesenchymal transition","volume":"119","author":"Kalluri","year":"2009","journal-title":"J Clin Invest"},{"key":"2023122107172263200_ljad335-B13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"2023122107172263200_ljad335-B14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of cancer: new dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov"},{"key":"2023122107172263200_ljad335-B15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000147748","article-title":"An overview of epithelio-mesenchymal transformation","volume":"154","author":"Hay","year":"1995","journal-title":"Acta Anat (Basel)"},{"key":"2023122107172263200_ljad335-B16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tcb.2018.12.001","article-title":"EMT transition states during tumour progression and metastasis","volume":"29","author":"Pastushenko","year":"2019","journal-title":"Trends Cell Biol"},{"key":"2023122107172263200_ljad335-B17","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2005304","article-title":"TGF-beta-induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops","volume":"7","author":"Zhang","year":"2014","journal-title":"Sci Signal"},{"key":"2023122107172263200_ljad335-B18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.bpj.2013.07.011","article-title":"Coupled reversible and irreversible bistable switches underlying TGF\u03b2\u200c-induced epithelial to mesenchymal transition","volume":"105","author":"Tian","year":"2013","journal-title":"Biophys J"},{"key":"2023122107172263200_ljad335-B19","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/med.21596","article-title":"Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis","volume":"40","author":"Feng","year":"2020","journal-title":"Med Res Rev"},{"key":"2023122107172263200_ljad335-B20","doi-asserted-by":"crossref","first-page":"6565","DOI":"10.1002\/jcp.26267","article-title":"Tumour-suppressive roles of DeltaNp63beta-miR-205 axis in epithelial-mesenchymal transition of oral squamous cell carcinoma via targeting ZEB1 and ZEB2","volume":"233","author":"Hashiguchi","year":"2018","journal-title":"J Cell Physiol"},{"key":"2023122107172263200_ljad335-B21","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.cell.2017.10.044","article-title":"Single-cell transcriptomic analysis of primary and metastatic tumour ecosystems in head and neck cancer","volume":"171","author":"Puram","year":"2017","journal-title":"Cell"},{"key":"2023122107172263200_ljad335-B22","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1038\/s41388-021-01868-5","article-title":"Partial EMT in head and neck cancer biology: a spectrum instead of a switch","volume":"40","author":"Pal","year":"2021","journal-title":"Oncogene"},{"key":"2023122107172263200_ljad335-B23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.pharmthera.2018.09.007","article-title":"Hybrid epithelial\/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas","volume":"194","author":"Jolly","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2023122107172263200_ljad335-B24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12964-020-00550-9","article-title":"A cancer stem cell-like phenotype is associated with miR-10b expression in aggressive squamous cell carcinomas","volume":"18","author":"Wimmer","year":"2020","journal-title":"Cell Commun Signal"},{"key":"2023122107172263200_ljad335-B25","doi-asserted-by":"crossref","first-page":"12954","DOI":"10.1038\/s41598-018-31061-w","article-title":"Evaluation of modified interferon alpha mRNA constructs for the treatment of non-melanoma skin cancer","volume":"8","author":"Hochmann","year":"2018","journal-title":"Sci Rep"},{"key":"2023122107172263200_ljad335-B26","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1158\/0008-5472.CAN-11-2996","article-title":"Fibroblast-derived dermal matrix drives development of aggressive cutaneous squamous cell carcinoma in patients with recessive dystrophic epidermolysis bullosa","volume":"72","author":"Ng","year":"2012","journal-title":"Cancer Res"},{"key":"2023122107172263200_ljad335-B27","doi-asserted-by":"crossref","first-page":"737272","DOI":"10.3389\/fgene.2021.737272","article-title":"Dystrophic epidermolysis bullosa: secondary disease mechanisms and disease modifiers","volume":"12","author":"Nystrom","year":"2021","journal-title":"Front Genet"},{"key":"2023122107172263200_ljad335-B28","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1093\/hmg\/ddu102","article-title":"Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-\u03b2\u200c signalling in modifying disease severity","volume":"23","author":"Odorisio","year":"2014","journal-title":"Hum Mol Genet"},{"key":"2023122107172263200_ljad335-B29","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022277","article-title":"TGF-\u03b2\u200c family signaling in tumour suppression and cancer progression","volume":"9","author":"Seoane","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2023122107172263200_ljad335-B30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1158\/0008-5472.CAN-15-1348","article-title":"Injury-driven stiffening of the dermis expedites skin carcinoma progression","volume":"76","author":"Mittapalli","year":"2016","journal-title":"Cancer Res"},{"key":"2023122107172263200_ljad335-B31","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jid.2020.10.024","article-title":"Diversity of mechanisms underlying latent TGF-\u03b2\u200c activation in recessive dystrophic epidermolysis bullosa","volume":"141","author":"Akasaka","year":"2021","journal-title":"J Invest Dermatol"},{"key":"2023122107172263200_ljad335-B32","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1016\/j.devcel.2021.11.006","article-title":"Distinct contributions of partial and full EMT to breast cancer malignancy","volume":"56","author":"Luond","year":"2021","journal-title":"Dev Cell"},{"key":"2023122107172263200_ljad335-B33","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1084\/jem.20181827","article-title":"Context-dependent EMT programs in cancer metastasis","volume":"216","author":"Aiello","year":"2019","journal-title":"J Exp Med"},{"key":"2023122107172263200_ljad335-B34","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8101542","article-title":"Dynamics of phenotypic heterogeneity associated with EMT and stemness during cancer progression","volume":"8","author":"Jolly","year":"2019","journal-title":"J Clin Med"},{"key":"2023122107172263200_ljad335-B35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"2023122107172263200_ljad335-B36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/cac2.12138","article-title":"EMT-associated microRNAs and their roles in cancer stemness and drug resistance","volume":"41","author":"Pan","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"2023122107172263200_ljad335-B37","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jare.2020.08.012","article-title":"Therapeutic advances of miRNAs: a preclinical and clinical update","volume":"28","author":"Chakraborty","year":"2021","journal-title":"J Adv Res"},{"key":"2023122107172263200_ljad335-B38","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2023122107172263200_ljad335-B39","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.7717\/peerj-cs.67","article-title":"OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs","volume":"2","author":"Anaya","year":"2016","journal-title":"Peerj Comput Sci"},{"key":"2023122107172263200_ljad335-B40","doi-asserted-by":"crossref","first-page":"110231","DOI":"10.1016\/j.biopha.2020.110231","article-title":"Non-coding RNAs in drug resistance of head and neck cancers: a review","volume":"127","author":"Dai","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"2023122107172263200_ljad335-B41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14194739","article-title":"Plasma-based microRNA expression analysis in advanced stage NSCLC patients treated with nivolumab","volume":"14","author":"Monastirioti","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2023122107172263200_ljad335-B42","first-page":"1453","article-title":"miR-200b and miR-200c co-\u00adcontribute to the cisplatin sensitivity of ovarian cancer cells by targeting DNA methyltransferases","volume":"17","author":"Liu","year":"2019","journal-title":"Oncol Lett"},{"key":"2023122107172263200_ljad335-B43","first-page":"75","article-title":"miR-200b regulates epithelial-\u00admesenchymal transition of chemo-resistant breast cancer cells by targeting FN1","volume":"24","author":"Yang","year":"2017","journal-title":"Discov Med"},{"key":"2023122107172263200_ljad335-B44","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/s41598-018-19384-0","article-title":"Exclusion from spheroid formation identifies loss of essential cell-cell adhesion molecules in colon cancer cells","volume":"8","author":"Stadler","year":"2018","journal-title":"Sci Rep"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad335\/52763365\/ljad335.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/1\/80\/54716080\/ljad335.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/1\/80\/54716080\/ljad335.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T07:23:40Z","timestamp":1703143420000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/1\/80\/7264090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,9,8]]},"published-print":{"date-parts":[[2023,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad335","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,9,8]]}}}